Lab automation in the drug discovery market was valued at USD 5.55 billion in the previous year and is expected to reach USD 7.28 billion while registering a CAGR of 4.12 percent during the forecast period. Drug discovery organizations have been investing massive amounts in R&D activities to develop new technologies that are expected to enhance their products. These companies invest in proteomics, drug testing, high-throughput screening, and combinational chemistry to develop an environment-friendly biotechnology reagent. Hence, such developments are expected to contribute to the growth of the market over the forecast period.
The market offers strong competition to the operating players, owing to the presence of some key players in the market, such as Thermo Fisher Scientific, Beckman Coulter, and Synchron Lab Automation. Their ability to innovate their offerings has allowed the players to gain a competitive advantage over their competitors. These players can gain a strong foothold in the market through R&D activities, strategic partnerships, and mergers and acquisitions.
In February 2023, PerkinElmer unveiled two new solutions aimed at next-generation screening and high-throughput screening (HTS) applications (NGS). The company unveiled its EnVision Nexus system, intended for demanding HTS applications and to hasten the drug development process. Due to the system's high-throughput, quick dual detectors, researchers can screen millions of samples more accurately, quickly, and sensitively. The company has made it possible for the system to be totally automated and integrated for continuous process automation. The company also unveiled the Zephyr G3 NGS iQ workstation, an integrated benchtop system that permits the automated production of up to 96 NGS libraries. This workstation includes a high-performance liquid handler, an integrated thermocycler, a robotic arm, and all deck accessories and peripherals, allowing laboratories to automate even the most complex NGS methods with a higher level of reproducibility, thereby increasing capacity and reducing errors.
In February 2022, The I.DOT HT Non-contact Dispenser and the L.DROP Liquid Handler were unveiled at SLAS 2022, according to DISPENDIX, a BICO firm. Driven by the I.DOT non-contact Dispenser's growth over the past few years, DISPENDIX made strategic R&D investments and industry partnerships to develop two innovative platforms that would work together to give scientists more comprehensive workflow solutions for genomics and drug discovery research. The I.DOT HT expanded on the I.DOT's basic technology uses a 384-well source well configuration to manage chemical libraries at big pharma and more modest biotechnology firms.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook